Skip to main content

Advertisement

Table 1 Subject-, disease-, and transplant-related variables

From: Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

Characteristics ATG-PTCy cohort (n = 114) ATG cohort (n = 125) P value
Recipient age (year, median, range) 27 (5–52) 24 (4–65) 0.004
HLA-matching (A, B, DR) 0.001
 3/6 94 (82%) 78 (62%)  
 4/6 or 5/6 20 (18%) 47 (38%)  
Recipient gender 0.35
 Male 63 (55%) 77 (62%)  
 Female 51 (45%) 48 (38%)  
Disease type 0.99
 Acute myeloid leukemia (AML) 55 (48%) 59 (47%)  
 Acute lymphoblastic leukemia (ALL) 47 (41%) 52 (42%)  
 Myelodysplastic syndromes (MDS) 9 (8%) 11 (9%)  
 Chronic myeloid leukemia (CML) 3 (3%) 3 (2%)  
Disease risk index 0.20
 Low/intermediate 101 (88%) 103 (83%)  
 High/very high 13 (12%) 22 (17%)  
Minimal residual disease at transplant 0.86
 Negative 93 (82%) 104 (83%)  
 Positive 21 (18%) 21 (17%)  
Donor source 0.19
 Mother 80 (70%) 98 (78%)  
 Collateral relatives 34 (30%) 27 (22%)  
  Donor gender male vs female 27 vs 7 20 vs 7  
  Donor age (year, median, range) 46 (12–67) 42 (10–61)  
  Maternal vs paternal line 20 vs 14 19 vs 8  
Donor gender 0.15
 Male 27 (24%) 20 (16%)  
 Female 87 (76%) 105 (84%)  
Donor-recipient pair 0.20
 Female to male 68 (60%) 64 (51%)  
 Others 46 (40%) 61 (49%)  
Donor age (year, median, range) 46 (12–67) 42 (10–61) 0.002
Blood type matching 0.020
 Match 51 (45%) 75 (60%)  
 Mismatch 63 (55%) 50 (40%)  
Median mononuclear cell (range, 108/kg) 8.2 (3.3–11.8) 10.4 (3.8–26.1) < 0.001
Median CD34+ cells (range, 106/kg) 1.9 (0.5–14.1)) 3.4 (1.6–21.2) < 0.001
Median CD3+ cells (range, 108/kg) 1.4 (0.3–5.7) 1.5 (0.3–11.1) 0.63
Year of transplant 0.006
 April 2015 to August 2016 40 (35%) 66 (53%)  
 September 2016 to June 2018 74 (65%) 59 (47%)  
Median follow-up (range, days) 587 (57–1399) 682 (3–1448) 0.20
Median follow-up in survivors (range, days) 661 (128–1399) 859 (230–1448) 0.007